Comparison of the efficacy of carboplatin, oxaliplatin and cisplatin, with various concentrations of epidermal growth factor family ligands, in killing human triple-negative breast cancer cells by Blankenship, Elise
Comparison of the efficacy of carboplatin, oxaliplatin and cisplatin, with
various concentrations of epidermal growth factor family ligands, in
killing human triple-negative breast cancer cells
An Undergraduate Honors Thesis
Elise Blankenship
Autumn 2011
Abstract
Current breast cancer therapies focus on the use of hormones to control tumor cells. However,
triple negative breast cancers (TNBC) lack receptors for the hormones estrogen and
progesterone, in addition to the HER-2 protein. As such, TNBC therapy is often limited to non-
targeted chemotherapeutic agents. Another receptor present on the cell surface of most TNBC
cells is epidermal growth factor receptor (EGFR), which could serve as a target for new
therapies. EGFR drives cell proliferation following its activation by epidermal growth factor
(EGF) family ligands. These ligands include amphiregulin, betacellulin, and EGF, which were
chosen for use in this study. Little research has been done on the use of EGF family ligands in
combination with established cancer therapies. EGF has been shown to have an effect on the rate
of cancer cell death when combined with platinum-based DNA alkylating agents in head and
neck cancers. In this combination therapy, the conflicting messages from the stimulating ligand
and the alkylating agent cause an enhanced rate of cell death apparently by more targeted and
efficient drug delivery to the cell nucleus. We have hypothesized that EGF family ligands can be
combined with alkylating agents for synergistic killing of EGFR-expressing TNBC cells. The
tests of hypothesis described here were pharmacological dose-response studies. Our results show
that different EGF family ligands have markedly different effects on EGF receptor trafficking
and subsequent cell death when combined with platinum drugs. To extend our results beyond
breast cancer cells, the treatments also were compared in another EGFR-expressing cancer
model, brain glioblastoma.
Introduction
Many advances in the treatment of breast cancer have occurred over the past 20 years. An
increase in the early detection of the disease, more sensitive screening in regards to tumor type,
and refined surgical procedures have all combined to reduce greatly the mortality risk associated
with the disease. One of the most significant advances in the treatment of breast cancer is with
adjuvant hormone treatment, including drugs such as tamoxifen, which acts as an estrogen
receptor antagonist.
There exist, however, hormone-negative cancers such as triple negative breast cancers
(TNBC), which lack receptors for estrogen and progesterone and the HER-2 protein, all common
targets of other breast cancer therapies. As such, current treatment regimens targeting these
receptors are useless to patients with TNBC. Treatment for these patients is often limited to
simple systemic chemotherapy and invasive surgery.  This fact, combined with the more
aggressive and metastatic nature of TNBC, gives patients a far more negative clinical prognosis.
Another characteristic of aggressive tumors, including TNBC, is the overexpression of
epidermal growth factor receptors (EGFR) (1). These receptors, when stimulated by epidermal
growth factor (EGF), trigger the cell to move into the growth cycle, and their overexpression is
correlated to an increased risk of metastasis and a more negative prognosis (2). EGFR is a
plasma membrane protein that stimulates cell growth. When activated, EGFR can be internalized
by the cell and degraded in lysosomes along with the signaling ligand. Therefore, treatment by a
substance that stimulates EGFR may cause a decrease in EGFR concentration on the cell surface
(referred to as downregulation), and with this a decrease in subsequent cell sensitivity to
stimulation (3). In addition to EGF, other ligands belonging to the EGF family are able to bind to
these receptors and cause receptor activation.
Figure 1. Cycle of EGFR when stimulated. When activated by EGF or another ligand, EGF is
internalized and moved into the endosome. At the late endosome phase, different effects of
distinct ligands can be observed. In specific cases, the
receptors are then degraded in the lysosome.
While binding of EGF results in receptor
internalization and degradation that signals cell growth,
other EGF family ligands vary in their resulting signals.
For example, amphiregulin (AMPHI) will bind to the
receptor and cause internalization, but the receptor
recycles back to the cell surface. This makes the ligand
an ideal control in experiments involving EGFR
downregulation. Betacellulin (BTC) binds tightly to the receptor, stimulating a high degree of
growth. However, BTC-stimulated receptors are driven efficiently toward lysosomes for
degradation.
Alkylating agents have been used in the treatment of aggressive metastatic cancers for
decades.  Currently, they are most commonly used to treat late-stage lung, ovarian, and brain
cancers. Alkylating agents induce G-C crosslinks in actively replicating DNA, and this
irreparable damage leads to cell death. Platinum-based alkylating agents are not commonly used
in breast cancer treatments, due to the high levels of resistance to cisplatin-induced toxicity (4).
The clinical use of alkylating agents also is limited by their severe side effects and frequent
toxicity, including severe anemia, esophageal ulceration, and bone marrow toxicity. It is
therefore very important to use alkylating agents at the lowest possible effective dose, in order to
minimize adverse effects on the patient while causing significant damage to the tumor.
Relatively little has been published about the use of EGF family ligands with alkylating
agents in cancer therapy.  Head and neck squamous cell carcinomas (HNSCC) overexpress
EGFR; they are more sensitive to alkylating agents when co-treated with EGF (5). Reported data
suggest that the targeting of EGFRs into the lysosomal degradation pathway is a critical
requirement for EGF-dependent enhancement of cell killing by cisplatin (1). We tested the
hypothesis that, when alkylating agents (which damage DNA) are combined with any EGF
family ligand that induces lysosomal degradation of EGFR, the two signals tell TNBC cells to
stop growing and grow, respectively, at the same time.  The conflicting messages thereby
enhance cell death.  Such a strategy could be useful for eliminating EGFR-positive tumors. This
enhanced level of cell death could reduce the amount of alkylating agent needed to cause tumor
remission. The growth signal given by the EGF family ligands will drive any cells in the resting
phase into the growth cycle, where they can be damaged by alkylating agents. Removing cells
from the resting phase at this stage of treatment may lower the rate of future recurrence.
Figure 2. Proposed mechanism of action of drug-ligand
combination therapy. EGFR, when stimulated, acts as a
“Trojan horse” in delivering the chemotherapeutic drug
to the cell.  The activated EGFR helps to internalize the
alkylating agent, delivering it to the cell nucleus more
efficiently than if the alkylating agent were added on its
own. Since the platinum-based compounds are used to
disrupt DNA but have a short active life, quick and
effective delivery to the nucleus increases the rate of cell
death in cancer cells. Since only the cancer cells are
overexpressing EGFR, this allows for greater delivery of
the drug specifically to tumor cells.
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Methods
Mammalian cell lines, their passage and maintenance.
Three types of mammalian cell lines were utilized in this study. For the TNBC model,
MDA-MB-231-luc-D3H1, an immortalized human adenocarcinoma of epithelial morphology
transfected with luciferase gene, was used. It was obtained commercially from Caliper Life
Sciences. MDA-MB-231 is a cancer cell type that lacks expression of estrogen, progesterone,
and HER-2 protein receptors, and overexpresses EGFR. This matches the characteristics of
TNBC, and the cell line has been shown to produce tumors in vivo in a mouse model (Caliper
Biosciences product information sheet, 2009, “Bioware Cell Line MDA-MB-231-luc-D3H1”,
www.caliperls.com/assets/018/7634/pdf). The presence of the luciferase gene will aid in imaging
studies in future experiments. Two types of glioma cells were kindly provided by Dr. R. Barth
for comparison to the breast cancer model. MDA-MB-F98 is a rat glioma cell line, with two
distinct sublines: EGFR Wild Type f (Wf) and EGFR Wild Type T5 (WT5). Wf has a high level
of EGFR expression, and the receptors can undergo phosphorylation after stimulation with an
EGF-family ligand. WT5 has a lower level of EGFR expression than Wf, but its receptors are not
efficiently phosphorylated upon ligand addition (personal communication, R. Barth). Preliminary
studies in the Lill laboratory indicate that only the WT5 receptors appear to undergo ligand-
induced degradation (unpublished).
All cell lines were passaged regularly at subconfluence, using a 0.25%trypsin/EDTA
solution and following an established laboratory protocol. The cells were maintained in “10%
Complete” DMEM containing 10% fetal bovine serum, 0.1 mM non-essential amino acids, 1
mM sodium pyruvate, 100 units/mL penicillin-streptomycin and 20 mM HEPES, in an
atmosphere containing 5% CO2.
Preparation of solutions used to treat cell lines.
All three cell lines were treated with several different types of alkylating agents and
EGFR family ligands. Cisplatin, carboplatin, and oxaliplatin were obtained from Sigma-Aldrich
in powdered form. Cisplatin was prepared in physiological saline (150mM NaCl) to generate a
0.1 mM stock and allowed to solubilize for 24 hours before use. Carboplatin and oxaliplatin were
prepared in a 10% dextrose solution to make 3mM and 2mM stocks, respectively, and were used
immediately. The stock solutions were used at varying dilutions to generate the working
concentrations indicated in the results section. Varying concentrations of EGF and AMPHI
obtained from Sigma were prepared in “10% complete” DMEM. BTC obtained from Peprotech
was prepared in “10% complete” DMEM.
Treatment of cells in vitro.
Cells were removed from dishes with trypsin/EDTA solution and seeded in 6-well cell
culture plates at a concentration of 1x10^5 cells per 9.4cm^2 well. Cells were allowed to grow
for 24 hours before treatment. At time of treatment, the media in all wells were removed and
replaced with the various treatment solutions as determined per experiment. Cells were then
allowed to grow undisturbed for a period of 5 days (for the breast cancer cell line) or a period of
6 days (for the glioma cell lines). Cells were then removed from the dishes using trypsin/EDTA
and resuspended in “10% complete” DMEM. Cell suspensions were then combined with 0.4%
trypan blue solution and live cells were counted using a Biorad TC10 cell counter.
Statistical Analysis.
For the in vitro experiments, the mean and standard deviation of three replicate samples
were calculated for each treatment type. A significant difference in matched treatment types was
found by calculating the p-value using the student’s t-test (α = 0.05). Analysis of variance
(ANOVA) was used to determine the significant difference between treatment levels. Triplicate
experiments were performed in all cases unless otherwise noted.
Results
Generation of cytotoxicity curves
In order to understand if a combination treatment will work more effectively than an
alkylating agent alone in killing MDA-MB 231 cells, a baseline needed to be established. We
wished to determine the minimal concentration at which cell death was barely detectable for all
three of the alkylating agents. By titrating within a broad range initially and then a narrower
range as needed, a break point in the curve of cell death with increasing drug concentration
should be observed.
The initial drug concentration range was based on published clinical doses. The common
clinical dosage for each drug (in mg/m2 of body surface area) was calculated in relation to
associated blood volume. The drug solution was prepared in the same vehicle in which the drug
is delivered clinically (physiological saline [150mM NaCl] for cisplatin or 10% dextrose solution
for carboplatin and oxaliplatin). Several dose ranges were titrated before the final level was
selected.
Cisplatin, considered the standard drug for these experiments, was titrated first. Cisplatin
was titrated within the concentration range of 0.001 to 5 microM. Dosages in this range were
applied to the MDA-MB-231 cells, and the surviving cells were quantified and compared to cells
treated with the NaCl vehicle only.
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Figure 3. MDA-MB 231 cell survival after 6-day treatment with cisplatin solution. The
concentrations of cisplatin used are shown on the x-axis. Averages of three independent
experiments and their standard deviations are shown.
The dosage of particular interest to us for future cytotoxicity experiments was the highest
dosage at which there was no observable cell death: this dosage is the threshold for determining
if a combination treatment will be more effective than an alkylating agent alone. If a significant
difference in killing at this drug level is achieved in combination treatment when ligand also is
added, the combination treatment can be said to have increased efficacy. Based on my data, the
dosage selected for future experiments was .001 microM (Figure 3).
The baseline molar dosages for carboplatin and oxaliplatin were calculated based on the
fact that they are considered to be half and one-third as effective as cisplatin, respectively. These
drug solutions were prepared in 10% dextrose, as per clinical use instructions. Cytotoxicity
curves for these drugs were generated in the same manner as the killing curves for cisplatin.
Based on the results of Figures 4 and 5, the baseline dosage for both carboplatin and oxaliplatin
is 50 microM.
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Figure 4. MDA-MB 231 cell survival after 6-day treatment with carboplatin solution. Details of
the experimental procedures are provided in the methods section. Averages of three independent
experiments and their standard deviations are shown.
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Figure 5. MDA-MB 231 cell survival after 6-day treatment with oxaliplatin solution. Details of
the experimental procedures are provided in the methods section. Averages of three independent
experiments and their standard deviations are shown.
The glioma cell lines WT5 and Wf were given the same drug dosages as the MDA-MB-
231 cells. This produced a similar cytotoxicity curves for these cells, allowing for a comparison
between the tumor types (Figure 6).
Figure 6. Wf (top) and WT5 (bottom) cell survival after 7-day treatment with cisplatin solution.
Details of the experimental procedures are provided in the methods section. Averages of three
independent experiments and their standard deviations are shown.
Once the useful baseline dosage of each alkylating agent had been determined, the ligand
EGF could be incorporated into controlled experiments to determine if there was a synergistic
increase in the levels of cell death. Different working concentrations of EGF were compared for
their effects on cell killing by each platinum drug.
For the comparisons in efficacy, the dosage of alkylating agent was held constant.
However, whether cells were incubated without or with cisplatin, EGF was titrated into the
cultures at increasing doses. The purpose here was to determine whether increasing levels of
EGF increasingly cooperated with the selected dose of alkylating agent. We predicted that, in
cells receiving no cisplatin, that increasing doses of EGF would have no impact on the number of
cells in each culture after 6 days of incubation: the cells receive all necessary amounts of EGF
from their culture media, which contains 10% serum. Additional EGF is expected to have no
further impact on total cell number. However, for cells receiving cisplatin with increasing doses
of EGF, we predicted that with increasing doses of ligand, more cisplatin would be delivered to
the cells resulting in enhanced cell death.
For cisplatin in MDA-MB 231 cells, increasing the dose of EGF increasingly enhanced
cell killing (Figure 7). The treatment showed no increased efficacy after the dosage of ligand
reached the level of 30 microM. This pattern was repeated in the carboplatin and oxaliplatin
treated samples (Figure 8).
Figure 7. MDA-MB 231 cells and cisplatin treated with varying amounts of EGF.
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Figure 8.MDA-MB 231 cells and oxaliplatin or carboplatin treated with varying amounts of EGF
Addition of EGF-family ligands to cells treated with alkylating agents
Other ligands in the EGF family may bind to the EGFRs present on the cell surface and
activate different signaling and trafficking pathways. BTC strongly stimulates receptors by
binding more tightly to the receptor; at saturating concentrations, it induces efficient EGFR
degradation (1). AMPHI binds to the receptor and causes internalization, but this ligand causes
the receptor to recycle back to the surface rather than undergoing lysosomal degradation.
Because of their different effects on EGFR signaling and fate, the three ligands were compared
for their impacts on tumor cell killing when combined with platinum-based chemotherapeutic
agents.
We assumed that BTC would enhance the rate of cell death when combined with an
alkylating agent to an even greater extent than EGF, due to the fact that it is most efficient in
inducing EGFR degradation (1). However, my experimental results indicated that no
enhancement of cell death was seen when BTC + alkylating agent was compared to alkylating
agent alone (Figure 9).
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Figure 9. MDA-MB 231 cells treated with varying amounts of BTC in the presence or absence
of cisplatin.
As this result was not expected, further examination of the effects of BTC on the MDA-
MB 231 cells was performed. An immunofluorescence study was performed, comparing the
EGFR fates in cells stimulated with EGF versus those stimulated with BTC (Figure 10). Based
on the dose-response and the immunofluorescence results, the ability of a combination therapy to
enhance tumor cell killing correlated best with the therapies ability to induce the translocation of
EGFR/Cbl complexes to the luminal vesicles of multivesicular endosomes (Figure 10).
Figure 10. Although both EGF and BTC target EGFRs for degradation, they differ in their
localization of EGFR/Cbl complexes at the late endosome stage.  COS-7 cells were stimulated
with EGF (left panel) or BTC (right panel) at 17 nM.  After 25 minutes of activation, images
were collected by fluorescence microscopy.  The green signals correspond to GFP-Cbl wt, which
is a marker for EGFR location in this experiment.  EGF causes EGFR/Cbl complexes to localize
to the luminal vesicles of late endosomes/multivesicular bodies.  BTC maintains the complexes
at the limiting membrane of these compartments (donut morphology).
Discussion
Alkylating agents cause a significant amount of cell death when acting alone. However,
they cause a number of detrimental side effects, as their toxicity is not specific for cancer cells.
This limits the amount of drugs that can be used to treat aggressive cancers and poses additional
risks to the patient. Using EGF family ligands in combination with these compounds may
enhance targeted killing of cancer cells while lowering cytotoxic effects on the body and the risk
of future recurrence.
The quantity of platinum drug needed to cause a reduction in tumor cell number is well
documented in the literature, both in clinical and in vitro settings. The calculated drug dosages
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used in this study were tested extensively. Cytotoxicity curves for all three of the alkylating
agents were generated. These data allowed us to identify the highest dosage that did not cause
cell death. This value was then used as the reference standard for whether or not combined
treatment was more effective than the alkylating agent alone. The control solution used was the
vehicle in which each drug was dissolved (physiological saline for cisplatin; 10% dextrose
solution for carboplatin and oxaliplatin), which allowed us to control for any effects caused by
the delivery vehicle.
When EGF was combined with an alkylating agent over a six day incubation period, an
enhanced rate of cell death was seen. By treating with EGF, growth was stimulated while
alkylating agent acted on the cells, causing effects leading to enhanced cell death. EGF at low
doses has been shown to induce receptor phosphorylation and internalization without recruitment
of the Cbl E3-ubiquitin ligase or significant EGFR ubiquitination. At higher dosese, EGF
stimulation leads to Cbl recruitment to activated receptors, with subsequent EGFR ubiquitination
and degradation in lysosomes. Our results show that an EGF dose of 3 microM is sufficient to
enhance cancer cell killing my cisplatin. Because this dose is expected to not induce receptor
ubiquitination, I propose that Cbl is not important to effect synergistic killing in combination
with platinum drugs in our model cell system.  However, we have not yet performed the
ubiquitination analyses necessary to demonstrate this unequivocally.
How might the ligand EGF selectively enhance tumor cell killing by platinum drugs?
Reports by other laboratories provide clues to the answer. Kroning and colleagues reported in
1995 that various malignant human cancers show increased sensitivity to platinum drugs when
co-treated with EGF (6). This observation was followed by Hambek et al., who showed that
prestimulation of head and neck cancer cells with EGF induced cell cycle entry by G0 phase
cells, rendering them susceptible to DNA-damaging agents (7). Both Ahsan and colleagues and
Mandic and collegues reported that many tumor cell lines that are resistant to cisplatin show
increased levels of death upon prior treatment with EGF (5, 8). The work of Ahsan et al. (5) went
further, revealing that cisplatin treatment increased EGFR phosphorylation at Y1045, which is
the Cbl recruitment site that must be phosphorylated in order to drive activated EGF receptors
through the endocytic pathway and toward lysosomes for degradation (1). Mutation of Y1045 to
phenylalanine resulted in abrogation of the ability of EGF to enhance cisplatin-mediated tumor
cell killing (5). Therefore, I extended the investigation of the mechanism of synergy by analyzing
whether distinct EGF family ligands, known to cause differential EGFR phosphorylation and
trafficking, also have differential impact on tumor cell killing platinum based drugs. Based on
my results shown here, I conclude that only EGF causes an increase in tumor cell death in
combination treatment with platinum based drugs. The combination treatment could have great
promise clinically in enhancing tumor cell death while minimizing the dosage of alkylating agent
required.
In conclusion, the combination treatment of EGF and alkylating agent enhances death in
TNBC cells in vitro. Further trials are warranted in animal studies to test the applicability of this
treatment in vivo.
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